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Abstract: Chronic hepatitis C (HCV) is a public health priority in the European Union/European
Economic Area (EU/EEA) and is a leading cause of chronic liver disease and liver cancer. Migrants
account for a disproportionate number of HCV cases in the EU/EEA (mean 14% of cases and >50%
of cases in some countries). We conducted two systematic reviews (SR) to estimate the effectiveness
and cost-effectiveness of HCV screening for migrants living in the EU/EEA. We found that screening
tests for HCV are highly sensitive and specific. Clinical trials report direct acting antiviral (DAA)
therapies are well-tolerated in a wide range of populations and cure almost all cases (>95%) and
lead to an 85% lower risk of developing hepatocellular carcinoma and an 80% lower risk of all-cause
mortality. At 2015 costs, DAA based regimens were only moderately cost-effective and as a result
less than 30% of people with HCV had been screened and less 5% of all HCV cases had been treated
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in the EU/EEA in 2015. Migrants face additional barriers in linkage to care and treatment due to
several patient, practitioner, and health system barriers. Although decreasing HCV costs have made
treatment more accessible in the EU/EEA, HCV elimination will only be possible in the region if
health systems include and treat migrants for HCV.
Keywords: hepatitis C; screening; migrants; viral hepatitis elimination; European Union
1. Introduction
Chronic hepatitis C is an important public health problem in the EU/EEA, with an estimated
3.24 million persons having active hepatitis C virus (HCV) infection [1,2]. It is a leading cause of
chronic liver disease and liver cancer in the EU/EEA due to undetected and untreated infections [3–5].
Since 2013, the landscape of HCV treatment has changed rapidly as pan-genotypic DAA HCV treatment
regimens that cure most infections (>95% of cases) have become available, making HCV elimination
possible [6–9]. In 2015 however, only 34% of HCV infected persons had been diagnosed and less than
5% of all HCV cases had been treated [2]. Identifying and treating all groups at risk for HCV in the
EU/EEA will be essential to address the health and economic burden due to HCV in the EU/EEA and
to reach WHO elimination goals by 2030 [3,5,9–11].
HCV screening and control programs in the EU/EEA primarily focus on persons who inject drugs
(PWID), as they are the largest and highest burden population [1]. Migrants from intermediate and
high HCV prevalence countries (anti-HCV ≥ 2% and ≥5%, respectively) are an additional important
and underappreciated group at increased HCV risk in the EU/EEA and often do not have identifiable
HCV risk factors [12,13]. They are most likely to have been exposed to HCV in their countries of
origin through receipt of contaminated blood products or unsafe injections or procedures, and have
a prevalence of HCV that reflects that of their countries of origin [14,15]. The increased flow of
migrants from intermediate and high HCV prevalence countries into the EU/EEA over the past few
decades has resulted in a disproportionately high number of reported HCV cases (14%) occurring
among migrants, who account for up to one half of all cases in some low HCV prevalence EU/EEA
countries [12,13]. HCV diagnosis among migrants living in low incidence countries is delayed due
to several patient, practitioner, and infrastructural barriers that may result in a higher burden of
liver-associated complications compared to host populations [16,17]. We conducted a systematic
review (SR) to estimate the effectiveness, resource use, costs, and cost-effectiveness of HCV screening
programs for migrants in the EU/EEA.
2. Methods
2.1. Overall Approach and Key Questions
Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)
approach, the Campbell and Cochrane Collaboration Equity Methods Group and review team
including clinicians, public health experts and researchers from across the EU/EEA, we conducted
evidence syntheses. “Migrants”, a focus of this review, included asylum seekers, refugees,
undocumented migrants, and other foreign-born residents. A detailed description of the methods
have been published and were registered in PROSPERO (CRD42016045798) [18].
We used the GRADE approach to rate the certainty of evidence starting with a simplified
categorization of study types (i.e., meta-analyses, RCTs, and observational studies). The rating
scheme allows for factors that may raise or lower the level of certainty. Factors that lower certainty
of evidence include, risk of bias, inconsistency across studies, indirectness, and publication bias.
Factors that increase certainty of evidence include large effect size and an observed dose-response
effect. The final certainty ratings are reflective of the certainty in the estimated effect in the context of
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bias and limitations. Evidence was graded as high, moderate, low, or very low certainty, based on how
likely further research would change the confidence in the estimate of effect. Low certainty and very
low certainty do not mean absence of evidence for effectiveness, but rather signal highlights the need
for more research to improve the precision of the estimate of effect.
This review followed the Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) and Cochrane methodological approach [18]. We used the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Checklist for reporting the
results of the systematic reviews (SR) [18,19]. The review team developed two overarching research
questions (PICO: Population, Intervention, Comparison, Outcome) and a logic model (Figure S1).
The logic model showed key questions/concepts along the evidence chain along the screening
effectiveness pathway [18,20,21]. The two overarching research questions (PICO) we sought to
answer were:
• What is the effectiveness of screening migrants arriving and living in the EU/EEA for HCV?
• What is the cost, resource utilization, and cost-effectiveness for screening migrants for HCV?
The following key questions were identified along the screening effectiveness pathway. (1) What
is the test accuracy and performance characteristics of screening tests for HCV? (2) What is the efficacy
of new direct acting antiviral (DAA) treatments for HCV to decrease HCV associated morbidity and
mortality? (3) What is the uptake of HCV of screening and treatment? (4) What is the cost-effectiveness
of a screen-treat approach for HCV in the general population and the migrant population when treated
with DAAs? [18].
2.2. Search Strategy and Selection Criteria
We conducted two searches, one for SRs and guidelines on the effectiveness and cost-effectiveness
of HCV screening programs in migrants and a second search for SRs and primary studies on the
resource use, costs, and cost-effectiveness of HCV screening programs in migrants. For the first
search, Medline via OVID, EMBASE, CINAHL, Epistemonikos, and Cochrane CENTRAL were
searched for publications between 1 January 2010 and 12 May 2016. A combination of key terms
was used including “hepatitis C/HCV”, “screening”, “migrants”, “costs”, “cost-effectiveness” AND
“guidelines”, and “reviews”. The search terms and the search strategy for Ovid Medline are included
in the supplementary material (Table S1). We also searched grey literature websites for published
guidelines and reports at CDC, ECDC, EASL (European Association for the Study of the Liver),
and WHO. We applied no language restrictions to the search. In the second search, using terms
of “hepatitis C/HCV”, “screening”, “costs”, and “cost-effectiveness”, Medline via Ovid, EMBASE,
the NHS Economic Evaluation Database (NHS EED), Database of Abstracts of Reviews of Effects
(DARE), and the Cost Effectiveness Analysis Tufts registry and Google scholar databases were searched
for publications between 1 January 2000 and 31 May 2016. Reference lists of relevant reviews were
also searched.
2.3. Study Selection and Quality Assessment
Two authors screened the titles and abstracts, assessed selected full-text articles for eligibility,
and extracted data from included articles. Disagreements were resolved by consensus or by a third
author. For the screening effectiveness search we included systematic reviews on the impact of HCV
screening or antiviral therapies on the development of liver related morbidities such as cirrhosis,
hepatocellular carcinoma, and the need for liver transplantation and all-cause or attributable mortality.
For the cost-effectiveness search we included individual economic studies of screening strategies that
included an arm of direct acting antiviral (DAA) therapies or studies of the cost-effectiveness of DAA
therapies [8]. We only included studies published in full and in English or French. If more than one
version of a SR was identified, the most recent was considered. Studies were excluded if they focused
only on nongeneralizable subgroups (such as PWIDs) (Figures 1 and 2).
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram for
the effectiveness of hepatitis C screening.
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The methodologic quality of SRs was assessed by two authors using the AMSTAR tool
(A Measurement Tool to Assess Systematic Reviews) [22]. The GRADE criteria were applied to
assess the certainty of evidence in preselected outcome measures in the SRs (GRADE Tables S2–S5) [23].
For the second search which included individual studies the certainty of economic evidence in each
study was assessed using the relevant items from the 1997 Drummond checklist [24].
2.4. Data Extraction and Synthesis
The following information was extracted from each study: study design, objectives, analyses,
quality of the individual studies included in the systematic review, population examined, number
of included studies, total number of participants included, intervention, outcome, and the results.
For the economic studies we extracted the following data; economic methods used (e.g., microcosting
study, within-trial cost–utility analysis, Markov model), description of the case base population,
the intervention and comparator, absolute size and relative difference in resource use, cost-effectiveness
results (e.g., incremental net benefit (INB) or incremental cost-effectiveness ratio (ICER)), and three
specific questions for the GRADE Evidence to Decision table: the size of the resource requirements,
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the certainty of evidence around resource requirements, and whether the cost-effectiveness results
favored the intervention or comparison [25]. Key results were converted to 2015 Euros using the
Cochrane web-based currency conversion tool: https://eppi.ioe.ac.uk/costconversion/default.aspx.
3. Results
3.1. Search Results
In the search for the effectiveness of HCV screening we retrieved 1475 references and identified
10 additional records through other sources (Figure 1). After duplicates were removed, 1459
references were screened by title and abstract. A total of 43 references were then selected for full
text assessment. We did not identify any randomized controlled trials or SRs on the effectiveness
of HCV screening in the general or migrant populations. We therefore included five SRs and one
guideline that addressed the key questions along the screening evidence chain: the performance of
HCV diagnostic tests (n = 2) [6,26], the impact of HCV treatment on preventing HCC and all-cause
mortality (n = 3) [27–29], and the HCV care continuum (n = 1) (Table 1) [30]. In the economic search,
682 articles were retrieved and an additional eight records identified through other sources (Figure 2).
After duplicate removal, 664 references were screened by title and abstracts. Of these, a total of 88
references underwent full text assessment and 14 individual studies of populations living in low HCV
prevalence countries were included (Table 2) [31–44].
3.2. Performance of Diagnostic Tests
The performance of diagnostic testing for HCV has been recently summarized in the 2017
WHO Guidelines on Hepatitis B and C testing [6]. WHO estimates the sensitivity and specificity
of 3rd generation HCV enzyme immunoassays (EIA) to be 98% and 99%, respectively [6]. Similarly,
the sensitivity of the confirmatory test to detect virus nucleic acid (nucleic acid test; NATs) is estimated
to be 96.2% (95% CI, 94.4–97.5) and the specificity to be 98.9% (98.3–99.3) [6]. There was no reported
evidence suggesting that migrants or any other group would encounter lower performance rates.
The accuracy of point of care testing, a strategy that potentially could increase screening uptake,
was reviewed by Khuroo et al. who found that these tests performed well in low, middle, and high
income countries [26]. The sensitivity (95.8% (93.9–97.1)) was slightly lower compared to EIAs but
demonstrated comparable specificity (99.0% (98.5–99.3)) [26]. The GRADE certainty of the evidence in
the Khuroo study was very low (S3 GRADE Table 1).
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Table 1. Characteristics of studies on the effectiveness of hepatitis C screening.
Study
Quality of Systematic
Review/GRADE
Certainty of Evidence
Design Population Intervention/Outcomes Results
Khuroo
2015 [26]
Quality of systematic
Review
AMSTAR: 8/11
GRADE Certainty of
Evidence
Very Low
Systematic Review
Up to March 2012.
N = 30 studies:
25—full-text article
2—WHO reports
1—WHO draft report
2—letters to editor
Adults > 18 years
17,151 participants
16 studies were conducted in
low/middle income countries
(India n = 4, Brazil n = 2, Cameroon n = 2,
China n = 2, Egypt n = 1, Malawi n = 1,
South Korea n = 2, Thailand n = 1, and
Zimbabwe n = 1)
14 studies conducted in high income
countries
(United States n = 8, Germany n = 1, Italy
n = 1, Spain n = 1)
(Report for WHO n = 3)
Intervention:
Point-of-care test: any commercially
available assay at or near the site of
patient care with <30 min
turn-around time. Reference
standard: third generation EIA,
microenzyme immunoassay, CIA,
RIBA, NAT
Outcome:
Sensitivity, specificity, LR+/−,
Diagnostic OR (95% CI)
Pooled sensitivity: 97.4% (95%
CI = 95.9–98.4)
specificity: 99.5% (99.2–99.7)
+LR: 80.17 (55.35–116.14)
−LR: 0.03 (0.02–0.04)
Diagnostic OR: 3032.85
(1595.86–5763.78)
OraQuick test had the highest
sensitivity and specificity:
sensitivity: 99.5 (98.9–99.8)
specificity: 99.8 (99.6–99.9)
Kimer
2012 [27]
Quality of systematic
Review
AMSTAR: 7/11
GRADE Certainty of
Evidence
Very Low
Systematic Review
Up to 2012
N = eight RCTs, five
prospective cohorts
RCTs conducted in France, Italy, Spain,
Japan, and USA in patients with
HCV-related cirrhosis or fibrosis and
treated with antiviral therapy 1156
patients with therapy
1074 controls
Prospective cohorts:
Patients with HCV-related cirrhosis
Intervention:
Antiviral therapy (PR, IFN, PEG-IFN)
Outcome:
RR, 95% CI of HCC development;
number needed to treat to prevent 1
case of HCC = 1/risk difference
overall mortality
liver-related mortality
liver-related morbidity
Risk of HCC among received
antiviral therapy vs. did not receive:
Absolute number of HCC: 81/1156
vs. 129/1174
RR (95% CI): 0.53 (0.34–0.81)
SVR and non-SVR compared to no
therapy—RR (95% CI):
SVR: RR = 0.15 (0.05–0.45)
Non-SVR: RR = 0.57 (0.37–0.85)
Number needed to treat to prevent
one case of HCC: eight patients.
Simmons
2015 [28]
Quality of systematic
Review
AMSTAR: 8/11
GRADE Certainty of
Evidence
Very low to low
Systematic Review
1990–2014
N = 31 studies:
General population: 17
studies;
Cirrhotic: nine studies;
HIV co-infected: five
studies
Adults (>18 years old) chronically
infected with HCV of any genotype
treated with any antiviral regimen
stratified into 3 groups:
1- patients at any disease stage
2- cirrhotic patients
3- HIV/HCV co-infected
Total: 33,336 participants
General population: 28,398
Cirrhotic: 2604
HIV co-infected: 2358
Intervention:
PR; IFN; PEG-IFN; IFN-beta
Outcome:
all-cause mortality;
pooled adjusted HR (95% CI); pooled
estimates for the 5-year mortality
Mortality of achieved SVR vs.
non-SVR, aHR (95% CI):
General population: 0.50 (0.37–0.67)
Cirrhotic group: 0.26 (0.18–0.74)
HIV co–infected group: 0.21
(0.10–0.45)
Pooled 5-year mortality rates for SVR
vs. non–SVR, IR (95% CI):
General population: 1.98 (1.00–3.45)
vs. 7.75 (5.86–10.98)
Cirrhotic group: 4.90 (3.45–7.28) vs.
15.88 (11.44–21.80)
Co–infected group: 1.49 (0.50–2.96)
vs. 11.44 (6.33–19.3)
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Table 1. Cont.
Study
Quality of Systematic
Review/GRADE
Certainty of Evidence
Design Population Intervention/Outcomes Results
Public Health Agency
of Canada, Canadian
Task Force on
Preventative Health
Care
2016 [29]
Quality of systematic
Review
AMSTAR: 11/11
GRADE Certainty of
Evidence
Very low to moderate
Systematic Review
Up to November 2015
N = Benefits of treatment:
11 studies;
Harms of treatment: 7
Treatment-naïve nonpregnant HIV/HBV
negative adults
Wide range of fibrosis scores +80%
noncirrhotic
RCTs (n = 7)
6/7 RCTs all patients were Genotype 1
2431 participants ranged from 121 to 499
participants in a study.
Recruitment sites included: United
States, Australia, Austria, Belgium,
Canada, Denmark, France, Germany,
New Zealand, Norway, Poland, Russia,
Spain, Japan, Italy, Mexico, Puerto Rico,
Romania, Ukraine, United Kingdom,
Sweden, the Netherlands, Bulgaria,
Portugal, Slovakia, China, and the
Republic of Korea.
Intervention:
DAA-based vs. PR regimens.
DDA therapies included those that
were approved at the time of the
study and those anticipated to be
approved by February 2016 for all
HCV genotypes.
Outcomes:
All-cause mortality;
hepatic mortality;
hepatic decompensation;
hepatocellular carcinoma;
need for liver transplantation.
Hepatic mortality: 60 fewer/1000
(95% CI 59–62)
Hepatocellular carcinoma: 18
fewer/1000 (17–19)
Decompensated cirrhosis: 46
fewer/1000 (46–47)
Need for liver transplantation: 4
fewer/1000 (4–6)
In cirrhotic individuals DAA–based
regimens compared to PR resulted in
30 fewer/1000 people affected by
hepatic mortality.
Yehia
2014 [30]
Quality of systematic
Review
AMSTAR: 3/11
Data quality not
formally assessed
Systematic Review
2003–2013
N = 10 studies
Only studies from the US that collected
data after 2000 were included.
Studies of the general population
excluded those with only a single study
site, exclusively focused on specific
populations (e.g., only immigrants,
injection drug users, those with
HIV/HCV co-infection)
Study subjects for each question
Chronic infection: 15,079
Diagnosed/Aware: 203
Access to Care: 101
HCV RNA confirmed: 8810
Liver biopsy: 180,703
Prescribed HCV treatment: 46,452
Achieved SVR: 18,105
Examined data addressing seven key
steps along the HCV care and
treatment cascade
Care/Treatment cascade:
100% Chronic HCV infected
(3,500,000)
50% Diagnosed and aware
43% Access to outpatient care
27% HCV RNA confirmed
17% Underwent liver biopsy
16% Prescribed HCV treatment
9% Achieved SVR
AMSTAR: A MeaSurement Tool to Assess systematic Reviews [22]; aHR: adjusted hazard ratio; CI: confidence interval; CIA: chemiluminescence immunoassay; DAA: direct acting
antiviral; EIA: enzyme immunoassay; GRADE: the grading of recommendation assessment, development and evaluation; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HIV:
human immunodeficiency virus; HR: hazard ratio; IFN: interferon; IR: incidence rate; LR: likelihood ratio; NAT: nucleic acid test; OR: odds ratio; PEG-IFN: pegylated interferon; PR:
pegylated-interferon-ribavirin; RBV: ribavirin; RCT: randomized controlled trial; RIBA: recombinant immunoblot assay; RNA: ribonucleic acid; RR: risk ratio; SVR: sustained virological
response; US: United States; WHO: World Health Organization.
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3.3. Impact of Therapy on Long-Term Outcomes
Interferon free DAAs are the recommended therapy for all HCV genotypes in the EU/EEA [8].
These regimens are well tolerated and cure > 95% of cases based on achieving sustained virologic
response (SVR0, which is considered to be a reliable surrogate outcome for HCV cure) [7,8]. Within the
search dates we did not identify any studies that examined the impact of DAA therapies on long-term
HCV liver related outcomes or mortality, as these agents only became available in 2013. Three SRs
that assessed the impact of older interferon (IFN) based HCV treatment on preventing liver related
sequelae and all-cause mortality were included [27–29]. These three SRs included studies from Europe,
North America, Australia, and Asia, and found that IFN-based HCV therapy significantly decreased
rates of hepatocellular carcinoma (HCC), hepatic decompensation, and all-cause mortality in those on
HCV treatment, and particularly in those who achieved SVR [27–29]. In a meta-analysis by Kimer et al.,
the risk of HCC was lower in those on antiviral HCV therapy (IFN or PEG-IFN alone or with ribavirin)
compared to placebo or no intervention (RR = 0.53, 95% CI 0.34–0.81). This effect was much more
pronounced among virological responders compared to nonresponders [27]. In the SR by Simmons
et al., the adjusted hazard ratio (aHR) of all-cause mortality rate was lower in patients on treatment
for chronic HCV after a median follow-up time of 5.4 years [28]. In those achieving SVR, compared
with non-SVR, the aHR was 0.50 (95% CI: 0.37–0.67) in the general population, and 0.26 (95% CI:
0.18–0.37) in the cirrhotic group [28]. Finally, in the SR conducted by the Public Health Agency of
Canada (PHAC), a reduction in hepatic mortality (60 fewer/1000, 95% CI: 59–62), HCC (18 fewer/1000,
95% CI: 17–19), hepatic decompensation or decompensated cirrhosis (46 fewer/1000, 95% CI: 46–47),
and need for liver transplantation (4 fewer/1000, 95% CI: 4–5) among those treated with DAA to
PEG-IFN was found [29]. The GRADE certainty of the evidence of the data in these three systematic
reviews was very low to moderate (GRADE Tables S3–S5).
3.4. The HCV Care Continuum and Pathway
In a SR of studies of the HCV care continuum in the pre-DAA period among in the general
population in the US from 2003–2013, only 50% of HCV cases were diagnosed and aware of their
infection, 27% had HCV RNA confirmatory testing, 16% were prescribed HCV therapy, and 9%
achieved SVR [30]. The results of this study were not stratified by risk group nor did they report on
the barriers to uptake of the steps along the care cascade. A modeling study in Europe published after
the search timeframe also demonstrated a weak HCV care continuum in 2015, consistent with the US
SR by Yehia [2]. They found that in Europe in 2015, only 36% of HCV infected persons have been
screened and, of those diagnosed, only 12.7% and 11.3% had been treated and cured, respectively [2].
They found that, to achieve WHO elimination targets, expansion of screening programs in the EU/EAA
would be needed along with unrestricted access to treatment for all found to be infected.
3.5. Resource Use, Costs and Cost-Effectiveness
Screening for HCV in those treated with DAAs is cost-effective even at higher 2015 costs. A UK
study evaluated the cost-effectiveness of screening and treating pregnant women attending antenatal
clinics [44]. The incremental cost effectiveness ratio (ICER) for screening and treatment (PR) compared
with no screening and no treatment was £2400 (€2745) per QALY gained. For screening and treating
with DAAs compared with no screening and no treatment, the ICER was still cost-effective at £9139
(€10,455)/QALY gained. A Canadian study evaluated the cost-effectiveness of screening for HCV
in different age groups and then treating with DAAs in the Canadian population where the HCV
seroprevalence ranged from 0.3 to 0.8% [32]. The ICER for IFN-free DAAs vs. older therapies ranged
from CAN$34,359 (€21,977) to CAN$44,034 (€28,166) per QALY gained [32]. In the US, Rein et al.
found that screening followed by DAA therapy was moderately cost-effective with ICERs ranging
from US$47,237 (€40,665) to US$72,169 (€62,128) per QALY gained [36].
Int. J. Environ. Res. Public Health 2018, 15, 2013 10 of 24
The Drummond Criteria [24]: (i) Was a well-defined question posed in answerable form? (ii)
Was a comprehensive description of the competing alternatives given (i.e., can you tell who did what
to whom, where, and how often)? (iii) Was the effectiveness of the program or services established?
(iv) Were all the important and relevant costs and consequences for each alternative identified? (v)
Were costs and consequences measured accurately in appropriate physical units (e.g., hours of nursing
time, number of physician visits, lost working days, and gained life years)? (vi) Were the cost and
consequences valued credibly? (vii) Were costs and consequences adjusted for differential timing?
(viii) Was an incremental analysis of costs and consequences of alternatives performed? (ix) Was
allowance made for uncertainty in the estimates of costs and consequences? (x) Did the presentation
and discussion of study results include all issues of concern to users?
Non-pan-genotypic DAA therapies have also been found to be moderately cost-effective, however
they had a large budget impact at the 2015 cost of treatment [31]. Deuffic-Burban found that DAAs were
moderately cost-effective for genotypes 1 and 4 regardless of fibrosis stage, ranging from €40,000 to
€88,000 per quality-adjusted life year (QALY) gained (Table 2). IFN-based regimens were estimated to
be more cost-effective for genotypes 2 or 3 at €21,300 to €19,400 per QALY gained regardless of fibrosis
stage [31]. DAAs were found to be moderately cost-effective for genotype 1 & 4 at a median threshold
of €24,000/QALY gained and maximum upper limit of €80,000/QALY gained however, introducing
these regimens on a wide scale would have a substantial budget impact of €3.5–7.2 billion on the
French health care system [31,45]. Several US studies have evaluated the cost-effectiveness of DAA
therapies compared to older PEG-INF-RBV therapies and found that DAA therapies were moderately
cost-effective at a willingness-to-pay threshold of $50,000 US (€39,210), but varied significantly by HCV
genotype, presence of liver fibrosis, and treatment history [33–38]. In the US, DAAs were moderately
cost-effective for genotypes 1 & 4 whereas IFN-RBV was more cost-effective for genotypes 2 & 3. DAAs
were more cost-effective in the presence of cirrhosis and treatment naïve patients. Providing DAAs to
all eligible HCV patients would also have a huge budget impact, costing an additional US$65 (€56)
billion over a 5-year period, whereas the resulting cost-offsets were estimated at only US$16 (€14)
billion [34].
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Table 2. Included studies on the cost, resource use, and cost-effectiveness of HCV screening and direct acting antiviral therapies.
Study Quality/Certainty ofEconomic Evidence Design/Population Intervention(s)
Cost-Effectiveness
(ICER or INB) Resource Requirements
Cost-effectiveness of HCV Screening and DAA therapy
Brett-Major
2016 [41]
Certainty of evidence:
moderate
Allowance was made for
uncertainty in the estimates of
costs, HCV rates, and ranges
were provided. Threshold
sensitivity analysis undertaken.
PSA not performed.
Justification for choice of ranges
was provided for all parameters.
Cost offsets (and net savings)
rather than cost-effectiveness
was reported
Design:
Decision-analytic costing model;
results reported in US dollars
Population:
Applicants to US military service
HCV prevalence 0.48–0.98/1000
Three strategies:
1- Enzyme immunoassay
(EIA) screening
2- EIA + nucleic acid testing
(NAT) screening
3- no screening
Treatment with SOF based
regimens
Not applicable
(Costing study)
High costs.
With no screening, the cost to the
Department of Defence of treating the
estimated 93 cases of chronic HCV cases
from a single year’s accession cohort was
$9.3 million [€7,293,134].
Screening with the HCV antibody test
followed by the nucleic acid test for
confirmation yielded a net annual savings
and a $3.1 million dollar [€2,431,044]
advantage over not screening.
He
2016 [42]
Certainty of evidence:
moderate
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA not performed.
Justification for choice of ranges
was not provided for all
parameters.
Cost-effectiveness results were
sensitive to the time horizon.
Design:
Dynamic microsimulation model
of transmission/progression of
HCV, and cost-effectiveness and
budget impact analysis; results
reported in US dollars
Population:
Population in US prisons
HCV prevalence 25% and 50%
undiagnosed
Three strategies:
1- risk-based screening
2- universal opt-out screening
3- no screening
Treatment with SOF based
regimens
ICER ($/QALY gained):
1 year risk-based vs. no screening: $19,635 [€15,552]
1 year universal vs. no screening:
$20,571 [€16,293]
5 year universal vs. no screening:
$24,046 [€19,046]
10 year universal vs. no screening: $29,234 [€23,155]
Low to moderate costs.
Screening cost per 2 million prisoners:
1year risk-based vs. no screening: +$37M
[€29M]
1year universal vs. no screening: +$107M
[€84M]
5year universal vs. no screening: +$178M
[€140M]
10year universal vs. no screening: +$249M
[€197M]
Treatment cost per 2 million prisoners:
No screening: $59,035M [€46,759M]
1year risk-based vs. no screening: +$816M
[€646M]
1year universal vs. no screening: +$1480M
[€1172M]
5year universal vs. no screening: +$1951M
[€1545M]
10year universal vs. no screening: +$2190M
[€1734M]
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Table 2. Cont.
Study Quality/Certainty ofEconomic Evidence Design/Population Intervention(s)
Cost-Effectiveness
(ICER or INB) Resource Requirements
Cost-effectiveness of HCV Screening and DAA therapy
Orkin
2016 [43]
Certainty of evidence: low
Allowance was not made for
uncertainty in the estimates of
costs and consequences. No
source for unit prices (costs)
was given.
PSA not performed.
Justification for choice of ranges
was not provided for all
parameters.
Cost-effectiveness results were
not reported.
Design:
Prospective 1 week-long
snapshot observational study
with assumed costs for testing
and treating; results reported in
British pounds
Population:
People visiting emergency
departments in the UK
HCV prevalence 1.84%
One strategy:
Routine combined HIV, HCV, and
HBV testing
Not applicable
Low to moderate costs.
Assuming the cost per diagnosis is £7 [€8],
the cost
per new case detected would be £988 [€1109]
for HCV, £1351 [€1517] for HBV. and £2478
[€2783] for HIV.
Rein
2015 [36]
Certainty of evidence: high
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA was performed.
Justification for choice of ranges
was provided for all parameters.
Cost-effectiveness results were
sensitive to treatment cost, SVR
probability, QALY post SVR,
fibrosis rate
Design:
Monte Carlo simulation model;
results presented in US dollars.
Population:
General population aged ≥20,
and patients with chronic HCV
genotype 1, 2, 3, and 4 in US
HCV prevalence rate: varies by
birth decade, race, and sex
Heavy alcoholics 0.089
HIV+ 0.02
Screening followed by treatment
Five strategies:
1- PR
2- PI+PR
3- SOF+PR
4- SOF+SIM
5- SOF+RBV
Genotype 1/4—ICER ($/QALY):
PR vs. no treatment: $59,792 [€47,359]
PR extensively dominated by PI+PR
PI + PR vs. no treatment:$43,530 [€34,478]
SOF+PR vs. PI+PR: $47,237 [€37,414]
SOF+SIM vs. SOF+PR: $72,169 [€57,162]
Treatment costs:
Genotype 1&4:
PR: $61,224 [€48,493]
PI+PR: $78,812 [€62,424]
SOF+PR: $99,306 [€78,656]
SOF+SIM: $150,360 [€119,094]
Genotype 2:
PR: $30,612 [€24,246]
SOF+RBV: $88,158 [€69,826]
Genotype 3:
PR: $30,612 [€24,246]
SOF+RBV: $176,316 [€139,653]
Other costs: Testing:
antibody: $25 [€19]
RNA: $59 [€45]
Post-diagnostic evaluation:
if coordinated with treatment: $832 [€658]
if not treated: $869 [€688]
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Table 2. Cont.
Study Quality/Certainty ofEconomic Evidence Design/Population Intervention(s)
Cost-Effectiveness
(ICER or INB) Resource Requirements
Cost-effectiveness of HCV Screening and DAA therapy
Selvapatt
2015 [44]
Certainty of evidence:
moderate
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA not performed.
Justification for choice of ranges
was not provided for all
parameters.
Cost-effectiveness results were
sensitive to the prevalence of
HCV infection among the
screened women and the
proportion of identified women
treated.
Design:
Markov cohort simulation model;
results reported in British pounds
Population:
Pregnant women attending
antenatal clinics in the UK
HCV prevalence 0.38%
Two strategies:
1- screening and treatment (PR)
2- no screening and
no treatment
Base-case: Treatment with PR
based regimen (IFN/RBV)
Additional scenarios:
1- IFN/RBV+SOF
2- IFN/RBV→ Ø SVR→
IFN/RBV+SOF
ICER (£/QALY):
Screening + PR vs. no screening + no treatment: £2400 [€2745]
(screening + newer direct-acting antiviral regimens vs. no screening + no
treatment: £9139 [€10,455])
Moderate costs.
Total costs of screening and confirmation of
44 new diagnoses: £240,641 [€275,299]
Cost per newly diagnosed individual: £5469
[€6256]
Wong
2015 [32]
Certainty of evidence:
moderate
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA was performed.
Justification for choice of ranges
was provided for all parameters.
Cost-effectiveness results were
sensitive to rates of chronic
HCV infection, seroprevalence,
costs (excluding the cost of
antiviral therapy), treatment
uptake and quality of life
(utilities).
Design:
Decision-analytic Markov model;
results reported in Canadian
dollars
Population:
General Canadian population, 2
age groups: 25–64 and 45–64
years old
HCV prevalence assumed is 0.5%
Four strategies:
1- No screening
2- Screen and treat with PR
3- Screen and treat with:
a G1: Interferon
free DAA
b G2/3: SOF+RBV
c G4/5/6: PR
4- Screen and treat with:
a G1: SIM+PR
b G2/3: SOF+RBV
c G4/5/6: PR
ICER (CAN $/QALY) of screening and treatment vs. no screening:
Age 25–64 years:
PR: $38,117 [€25,502]
IFN-free DAA (genotype 1), SOF+RBV (genotype 2/3),or PR (genotype 4/5/6):
$34,783 [€23,271]
PR+RBV (genotype 1), SOF+RBV (genotype 2/3), or PR (genotype 4/5/6):
$42,398 [€28,366]
Age 45–64 years:
PR: $34,359 [€22,988]
SIM+PR (G1), SOF+RBV (G2/3), or PR (G4/5/6): $44,034 [€29,461]
IFN-free DAA (G1), SOF+RBV (G2/3), or PR (G4/5/6): $35,562 [€23,793]
Moderate to high costs:
CAN$70,000 [€46,834] $84,000
[€56,201]/person.
Costs of antiviral therapies (CAN $):
SIM-based: 24 weeks: $46,157 [€30,881];
48 wk: $55,811 [€37,340]
SOF-based: 12 wk: $55,000 [€36,798]
ABT-based: 48 wk: $19,948 [€13,346];
24 wk: $9974 [€6673]
Costs of adverse events (weekly):
anemia: $107 [€71], depression: $73 [€48],
pruritus: $12 [€8], rash: $12 [€8]
HCV-tests:
anti-HCV: $14 [€9], HCV RNA: $100 [€66]
For age 25–64 years,
No screening: $71,327 [€47,722];
Screen and treat:
PR: $71,450 [€47,804]
IFN-free DAA (G1), SOF+RBV (G2/3) or PR
(G4/5/6):
$71,593 [€47,900]
SIM+PR (G1), SOF+RBV (G2/3) or PR
(G4/5/6):
$71,593 [€47,900]
For age 45–64:
No screening: $83,335 [€55,756]
Screen and treat:
PR: $83,476 [€55,850]
IFN-free DAA (G1), SOF+RBV (G2/3) or PR
(G4/5/6):
$83,672 [€55,981]
SIM+PR (G1), SOF+RBV (G2/3) or PR
(G4/5/6):
$83,673 [€55,982]
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Table 2. Cont.
Study Quality/Certainty ofEconomic Evidence Design/Population Intervention(s)
Cost-Effectiveness
(ICER or INB) Resource Requirements
Cost-effectiveness of HCV Screening and DAA therapy
Chhatwal
2015 [34]
Certainty of evidence: high
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA was performed.
Justification for choice of ranges
was provided for all parameters.
Cost-effectiveness results were
most sensitive to quality of life
after successful treatment, cost
of SOF, drug efficacy
Design:
Decision-analytic Markov model;
results reported in US dollars
Population:
Treatment naïve and
treatment-experienced HCV
population in US
Two strategies:
1- SOF-LDV
2- IFN-based therapy
SOF-LDV vs. IFN-based therapy—ICER ($/QALY):
Treatment naïve patients:
No cirrhosis: $61,517 [€48,725.]
Cirrhosis: $20,673 [€16,374]
Treatment experienced patients:
No cirrhosis: $69,707 [€55,212]
Cirrhosis: $92,302 [€73,109]
Treating eligible HCV patient would cost an
additional $65 billion [€51.5 billion] over a 5
year period
The weekly costs by third-party payer
SOF: $7000 [€5544]
LDV: $875 [€693]
PEG-IFN: $587 [€464]
RBV: $309 [€244]
BOC: $1100 [€871]
TEL: $4100 [€3247]
Deuffic-Burban
2016 [31] *
Certainty of evidence:
moderate
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA not performed.
Limited justification for choice
of ranges.
Cost-effectiveness results were
sensitive to the price of new
DAAs particularly for treating
genotype 1
Design:
Decision-analytic Markov model;
results reported in Euros
Population:
Patients with chronic HCV aged
≥18, aware of their infection, in
fibrosis stage F0–F4 or
decompensated cirrhosis, treated
in France.
HCV prevalence
Three strategies:
1- TVR/BOC-based triple
therapy for genotype 1 and
dual therapy with PR for
genotypes other than 1 (at F2)
2- SOF/SIM+PR
3- IFN-free DAAs with or
without RBV
Strategies 2 & 3 evaluated starting
treatment at ≥F3, ≥F2 or
regardless of fibrosis
Genotype 1:
IFN-free was a cost-effective vs. IFN-based:
ICER: €40,400 to €88,300/QALY
QALY/person: 12.59 vs. 12.11 for IFN-based therapy
Genotypes 2 or 3:
IFN-based was the most cost-effective:
ICER: €21,300/QALY for genotype 2
ICER: €19,400/QALY for genotype 3
Genotype 4:
IFN-free regimens was cost-effective:
ICER: €23,000 to €58,200/QALY
Moderate to high resource
Treating all CHC-screened patients over 5
years would cost: €3.5–7.2 billion
Cost of treatment/week:
SOF: €3417
OBV/PTV-r: €3259
DCV: €2125
SIM: €1750
TEL: €1042
LDV: €417
BOC: €378
DAV: €284
PEG-IFN: €158
RBV: €55
Costs related to adverse events (cost per
event):
Severe anaemia: €2564
Severe depression: €1619
Severe rash: €2942
Moderate anaemia: €4200
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Study Quality/Certainty ofEconomic Evidence Design/Population Intervention(s)
Cost-Effectiveness
(ICER or INB) Resource Requirements
Cost-effectiveness of HCV Screening and DAA therapy
Hagan
2014 [37]
Certainty of evidence:
moderate
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA not performed.
Justification for choice of ranges
was provided for all parameters.
Cost-effectiveness results were
sensitive to SVR rates
Design:
Decision-analytic Markov model;
results reported in US dollars
Population:
Chronic HCV genotype 1, in 50
years old in US
HCV prevalence 1.6%
Two strategies:
1- SOF/RBV
2- SOF/SIM
SOF-SIM dominated SOF-RBV: yielded lower costs and more QALYs
SOF-SIM: $165,336 [€133,108]
and 14.69 QALYs
SOF-RBV: $243,586 [€196,106]
and 14.45 QALYs
Costs of drugs per course:
24-weeks SOF/RBV: $169,000
12-weeks SOF/SIM: $150,000
Treatment-associated medical care:
SOF/RBV: $2100 (1890–2310)
[€1690 (€1521–€1859)]
SOF/SIM: $1160 (1044–1276)
[€933 (€840–€1027)]
Leidner
2015 [40]
Certainty of evidence:
moderate
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA not performed.
Justification for choice of ranges
was provided for all parameters.
Cost-effectiveness results were
sensitive to post-treatment
quality of life (utilities) and
treatment costs.
Design:
Decision-analytic Markov model;
results reported in US dollars
Population:
55-year old patient in US with
genotype 1 HCV infection
Two strategies:
1- treatment at fibrosis stages F3
and F4
2- treatment strategies at earlier
stages of liver disease
(fibrosis stages F2, F1, or F0).
ICER ($/QALY):
Patients diagnosed at F0:
treatment at F2 vs. F3: $97,900 [€80,102]
treatment at F0 vs. F2: $242,900 [€198,741]
Patients diagnosed at F1:
treatment at F2 vs. F3: $59,500 [€48,683]
treatment at F1 vs. F2: $174,100 [€142,449]
Patients diagnosed at F2:
treatment at F2 vs. F3: $37,300 [€30,518]
The threshold of treatment costs:
for ICER $50,000/QALY: $20,200 [€16,527]
for ICER $100,000/QALY: $42,400 [€34,691]
Moderate to high costs.
Larger costs for patients with advanced or
end stage liver disease, compared to early
stage liver disease.
Nontreatment and treatment costs:
Patients starting at F0:
treatment at F3: $33,600 [€27,491]
treatment at F2: $45,000 [€36,819]
treatment at F1: $70,800 [€57,928]
treatment at F0: $11,100 [€9082]
Patients starting at F1:
treatment at F3: $59,200 [€48,437]
treatment at F2: $77,400 [€63,328]
treatment at F1: $113,200 [€92,620]
Patients starting at F2:
treatment at F3: $91,000 [€74,456]
treatment at F2: $113,600 [€92,947]
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Cost-Effectiveness
(ICER or INB) Resource Requirements
Cost-effectiveness of HCV Screening and DAA therapy
Linas
2015 [39]
Certainty of evidence: high
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA was performed.
Justification for choice of ranges
was provided for all parameters.
Cost-effectiveness results were
sensitive to cost of SOF
Design:
Monte Carlo simulation. Results
reported in US dollars
Population:
Chronic HCV genotype 2 or 3 in
the US
Three strategies:
1- SOF
2- PR
3- No therapy
ICER ($/QALY)
Genotype 2
No cirrhosis (naïve):
24 wk PR vs. no therapy:
$3000 [€2415]
12 wk SOF-RBV vs. 24 wk PR:
$238,000 [€191,609]
No cirrhosis (treatment experienced):
12 wk SOF-RBV vs. no therapy:
$63,700 [€51,283]
16 wk SOF-RBV vs. 12 wk SOF-RBV:
$468,000 [€376,777]
Cirrhosis (treatment naïve):
24 wk PR vs. no therapy:
$8700 [€7004]
12 wk SOF-RBV vs. 24 wk PR:
$35,500 [€28,580]
Cirrhosis (treatment experienced):
12 wk SOF-RBV dominated by no therapy
SOF-RBV 16 wk vs. 12 wk:
$27,300 [€21,978]
Genotype 3
No cirrhosis (treatment-naïve):
24 wk PR vs. no treatment:
$4800 [€3864]
12 wk SOF-RBV dominated by 24 wk PR
12 wk PR-SOF vs. 24 wk PR:
$263,000 [€211,736]
24 wk SOF-RBV vs. 12 wk PR-SOF:
$266,000 [€214,151]
No cirrhosis (treatment-experienced):
12 wk PR-SOF vs. no treatment:
$82,000 [€66,016]
12 wk SOF-RBV and 16 wk SOF-RBV both dominated by 12 wk PR-SOF
SOF-RBV 24 wk vs. 16 wk:
$1,100,000 [€805,080]
Cirrhosis (treatment-naïve):
24 wk PR vs. no treatment:
$13,600 [€10,949]
12 wk SOF-RBV dominated by 12 wk PR
12 wk PR-SOF vs. 24 wk PR:
$22,600 [€18,194]
24 wk SOF-RBV vs. 12 wk PR-SOF:
$107,000 [€86,143]
Cirrhosis (treatment-experienced):
12 wk PR-SOF vs. no treatment:
$22,300 [€17,953]
12 wk, 16 wk and 24 wk SOF-RBV all dominated by 12 wk PR-SO
Total HCV therapy costs per number of
weeks (base case value and range from
sensitivity analysis):
24 wk PR: $25,300 (12,800–37,800)
[€20,368 (10,305–30,432)]
12 wk SOF–RBV: $91,500 (2000–97,500)
[€73,664 (1610–78,495)]
16 wk SOF–RBV: $121,900 (30,000–129,900)
[€98,139 (24,152–104,579)]
24 wk SOF–RBV: $182,900 (4900–194,900)
[€147,249 (3944–156,910)]
12 wk PR-SOF: $9000 (3000–$105,000)
[€7245 (2415–84,533)]
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Najafzadeh
2015 [33]
Certainty of evidence: high
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA was performed.
Justification for choice of ranges
was provided for all parameters.
Cost-effectiveness results were
sensitive to treatment cost
Design:
Discrete event simulation
Population:
Treatment-naive patients infected
with chronic HCV genotype 1, 2,
or 3 in the US.
Five strategies (genotype 1)
1- BOC+PR
2- SOF+PR
3- SOF+SIM
4- SOF+DCV
5- SOF+LDV
4 strategies (genotype 2/3):
1- PR
2- SOF+RBV
3- SOF+DCV
4- SOF+LDV+ RBV (genotype
3 only)
ICER ($/QALY):
Genotype 1
BOC+PR: reference
SOF+PR: $21,528 [€17,051]
SOF+SIM: $71,445 [€56,589]
SOF+DCV: $63,355 [€50,181]
SOF+LDV: $12,825 [€10,158]
Genotype 2:
PR: reference
SOF+RBV: $110,168 [€87,260]
SOF+DCV: $691,574 [€48,770]
Genotype 3:
PR: reference
SOF+RBV: dominated by PR
SOF+DCV: $396,229 [€313,839]
SOF+LDV+RBV: $73,236 [€58,007]
Drug costs:
Genotype 1:
BOC+PR: $100,926 [€79,940]
SOF+PR: $120,648 [€95,561]
SOF+SIM: $171,023 [€135,461]
SOF+DCV: $169,747 [€134,450]
SOF+LDV: $115,358 [€91,371]
Genotype 2:
PR: $54,005 [€42,775]
SOF+RBV: $109,958 [€87,093]
SOF+DCV: $316,845 [€250,962]
Genotype 3:
PR: $58,323 [€46,195]
SOF+RBV: $207,872 [€164,648]
SOF+DCV: $317,830 [€251,742]
SOF+LDV+RBV: $120,464 [€95,415]
Saab
2014 [38]
Certainty of evidence:
moderate
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA was performed.
Justification for choice of ranges
was not provided for all
parameters.
Cost-effectiveness results were
most sensitive to cirrhosis
prevalence and fibrosis rate,
recurrence rates in patients
achieving SVR.
Design:
Decision-analytic Markov model;
results reported in US dollars
Population:
Patients with chronic HCV
genotype 1 in US
Five Strategies:
1- SOF+PR
2- PR
3- BOC+PR
4- TEL+PR
5- SIM+PR
ICER ($/QALY):
Treatment naïve (without cirrhosis)
SOF+PR compared with
PR: ≤$29,271 [€23,565]
No treatment: $2071 [€1667]
SOF+PR dominated BOC+PR, TEL+PR and SIM+PR
Treatment naïve (with cirrhosis)
SOF+PR compared with
PR: ≤$16,939 [€13,637]
BOC+PR: $8450 [€6802]
SIM+PR: $1899 [€1528]
No treatment: $17,299 [€13,927]
SOF+PR dominated TEL+PR
Treatment experienced (all patients)
SOF+PR compared with
PR: ≤$4290 [€3453]
No treatment: $16,617 [€13,378]
SOF+PR dominated BOC+PR, TEL+PR and SIM+PR
Total lifetime costs:
Treatment-naïve without cirrhosis:
SOF+PR: $116,715 [€93,964]
PR: ≤$95,333 [€76,750]
BOC+PR: $124,229 [€100,014]
TEL+ PR: $128,879 [€103,757]
SIM+PR: $120,318 [€96,865]
No treatment: $112,093 [€90,243]
Treatment-naïve with cirrhosis:
SOF+PR: $209,923 [€169,004]
PR: ≤$172,814 [€139,129]
BOC+PR: $199,192 [€160,365]
TEL+ PR: $211,996 [€170,673]
SIM+PR: $207,758 [€167,261]
No treatment: $140,210 [€112,880]
Treatment-experienced all patients:
SOF+PR: $148,812 [€119,805]
PR: ≤$145,009 [€116,743]
BOC+PR: $165,983 [€133,629]
TEL+ PR: $165,428 [€133,182]
SIM+PR: $168,251 [€135,455]
No treatment: $115,911 [€93,317]
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Younossi
2015 [35]
Certainty of evidence:
moderate
Allowance was made for
uncertainty in the estimates of
costs and consequences, and
ranges were provided.
PSA was performed.
Justification for choice of ranges
was not provided for patient
distribution, regimen efficacy,
costs, or utilities.
Cost-effectiveness results were
robust across the limited ranges
tested.
Design:
Decision-analytic Markov model;
results reported in US dollars
Population:
Patients with chronic HCV
genotype 1 in US.
Six strategies:
1- LDV/SOF
2- SOF+PR
3- SIM+PR
4- SOF+SIM
5- SOF+RBV
6- BOC+PR
LDV/SOF (ICER):
Treatment-naïve patients:
dominant over no treatment
dominant over SOF+PR (12/24 weeks)
less expensive and less effective than SOF+SIM
dominant over SOF+RBV
dominant over BOC+PR
Results similar for patients with and without cirrhosis; and for treatment
experienced patients with PR or Protease inhibitor (PI) + RBV
Drug costs/pack:
BOC: $6687 [€5296]
LDV/SOF: $31,500 [€24,950]
PEG-IFN: $3310 [€2621]
SIM: $22,120 [€17,520]
SOF: $28,000 [€22,177]
RBV: $1153 [€913];
Generic: $238 [€188]
Total lifetime costs by strategy (treatment
naïve):
No treatment: $141,856 [€112,359]
LDV/SOF: $90,127 [€71,386]
SOF+PR: $119,846 [€94,925]
SIM +PR: $128,793 [€102,012]
SOF+SIM: $191,631 [€151,784]
SOF+RBV: $229,200 [€181,541]
BOC+PR: $127,759 [€101,193]
ABT: a protease inhibitor; BOC: boceprevir; CAD: Canadian dollar; DAA: direct acting antiviral; DAV: dasabuvir; DCV: daclatasvir; F: fibrosis stage; G: genotype; HBV: hepatitis B virus;
HCV: hepatitis C virus; HIV: human immunodeficiency virus; ICER: incremental cost-effectiveness ratio; IFN: interferon; INB: incremental net benefit LDV: ledipasvir; OBV: ombitasvir; PI:
protease inhibitor; PEG-IFN: pegylated interferon; PR: pegylated-interferon-ribavirin; PSA: probabilistic sensitivity analysis; PTV-r: paritaprevir-ritonavir; QALY: quality-adjusted life
years; RBV: ribavirin; RNA: ribonucleic acid; SIM: simeprevir; SOF: sofosbuvir; SVR: sustained virological response; TEL/TVR: telaprevir; US: United States. * Costs were expressed in 2015
Euro in the original publication.
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4. Discussion
The data in this review supports the effectiveness and cost-effectiveness of HCV screening in
populations at risk for HCV infection, including migrants from intermediate and high HCV prevalence
countries (anti-HCV ≥ 2% and ≥5%, respectively). Screening tests to detect the presence of HCV
antibodies performed equally well in all populations. In the laboratory setting or at the point-of-care
both are highly sensitive and specific [6,26]. DAA therapies are highly efficacious and well tolerated
with >95% cure rates in a range of populations in different countries [7]. Achieving SVR with HCV
therapy is associated with decreased risk and rate of liver disease progression, lower rates of HCC
development, and improved survival [27–29,46]. At 2015 costs, DAA based regimens were only
moderately cost-effective and as a result less than 30% of those with HCV had been screened and less
than 5% of all HCV cases had been treated in the EU/EEA in 2015 [2,31]. Migrant populations in the
EU/EEA face difficulties accessing care and treatment as a result of numerous barriers at the patient,
provider, and health system level [16,47]. To reach HCV elimination goals in the EU/EEA dramatic
scale up of HCV testing with diagnosis of all groups at HCV risk, including migrants, and linking
those found to be positive to care and treatment will be required.
Migrants living in the EU/EEA bear a disproportionate burden of HCV [1,13]. They are older and
more likely to have advanced liver disease and hepatocellular carcinoma compared to non-migrants
at the time of HCV diagnosis [17,48,49]. This is likely due to missed or delayed diagnoses. In a
survey in Finland, 63% of migrants found to be HCV positive had not been previously diagnosed [50].
Seventy percent of these HCV positive migrants had been living in Finland for more than five years.
Similarly, in a population based study in Canada, it took a mean of 10 years after arrival for migrants
to be diagnosed with HCV [48]. Another Canadian study found that it was cost-effective to screen
immigrants for HCV followed by DAA treatment at an anti-HCV prevalence of 1.9%, which is the mean
HCV seroprevalence of migrants living in the EU/EEA [12,13,51]. These data taken together suggest
that early screening of migrants based on the HCV prevalence in the country of origin with linkage
to care and treatment could prevent liver related sequelae in the migrant population and would be
cost-effective. In an ECDC survey, 18 of 21 responding countries had national guidance on HCV testing;
however, only six countries (29%) had guidance on testing migrants for HCV [52]. This highlights an
important gap and an opportunity for health promotion among the migrant population.
Migrants face multiple barriers in accessing healthcare services resulting in gaps along all steps of
the HCV care continuum [16,53]. Many groups of newly arriving migrants, including asylum seekers
and undocumented migrants, lack entitlement to health care in the EU/EEA, thus preventing them
from being diagnosed or receiving treatment [54]. Individual barriers include lack of knowledge and
awareness of risk factors, fear, and stigma of blood-borne diseases, and socioeconomic, linguistic,
and cultural barriers [47,55–57]. Providers are frequently unaware that birth in an HCV endemic
country is an important risk factor for HCV. Language and cultural discordance between patients
and providers may lead to poor communication and low quality of care [16,53,58]. Lack of screening
guidelines and programs and the lack of access to interpreters are important health system barriers.
Barriers to effective screening and treatment programs may also include lack of political will to address
migrant health issues or negative national attitudes toward migrants. Resulting policies may deny
migrants the entitlement to health care or prevent the development of migrant-friendly heath care
systems [58].
Evidence from primary studies of migrant populations suggests that HCV screening uptake
and linkage to care could be improved by implementing decentralized community-based screening
strategies, and cooperation with community-based organizations to overcome cultural and language
barriers [59–64]. Furthermore, integrated point-of-care testing for HCV, HBV, and HIV increased
testing uptake [59,65]. HCV screening and treatment programs for migrants in the EU/EEA will need
to be tailored to their specific needs. In addition, it will be necessary to ensure universal access to
health care in order to enhance uptake along the entire HCV care continuum.
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The greatest barrier to scaling up HCV treatment in the EU/EEA has been the high cost of therapy,
which has decreased dramatically in the past two years [66]. As a result, many countries in the EU/EEA
have lifted restrictions and provide more widespread availability of HCV therapy in the region [67].
Dropping prices and simpler short treatment regimens have helped create an opportunity to eliminate
HCV in the EU/EEA. Recent guidance from the WHO has highlighted the need to increase HCV case
detection and linkage to HCV care [6]. This includes screening persons originating from countries with
an intermediate (≥2%) and high (≥5%) HCV prevalence, which includes many of the migrants living
in the EU/EEA. Consideration of existing prevention and control efforts and the capacity of existing
systems must also be taken into account [68]. Knowledge of the HCV epidemiology in each EU/EEA
Member State will be needed to identify those migrant groups at highest HCV risk, given that the top
countries of origin of HCV infected migrants in each country varies (Table S6) [13]. Each country will
need to assess their own capacity to increase HCV testing in at risk populations and to ensure that
programs are in place that effectively link those with active HCV to care and provide HCV treatment.
Strengths and Limitations
The major strength of our study is that we used a systematic review process to identify relevant
studies and the GRADE methodology to evaluate the certainty of the evidence. Our study had the
following limitations. The findings were limited by the low to moderate certainty of the evidence of
the included studies. Our study was also limited by the low number of studies reporting on linkage to
care for migrants to EU/EEA. Finally, the included cost-effective studies modeled the 2015 cost of DDA
therapies. We anticipate however, that HCV screening and treatment will be even more cost-effective
given the dramatic decrease in cost of DAA therapy in the EU/EEA since 2015 [66,67].
5. Conclusions
In many EU/EEA countries migrants originating from intermediate and high HCV prevalence
countries make up a large proportion of all HCV cases and have poorer liver related outcomes due
to delayed diagnosis and treatment. This health disparity is due to the numerous barriers migrants
face accessing HCV diagnosis, care, and treatment. Migrant focused programs will need to ensure
entitlement to health services and will be most effective if they address linguistic and cultural barriers,
are community-based, and integrated with screening for other diseases such as HIV and HBV. Although
decreasing HCV costs have made treatment more accessible in the EU/EEA, HCV elimination will
only be possible in the region if health systems include and treat migrants for HCV [66].
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/15/9/2013/
s1, Figure S1: Analytic Framework for HCV Screening in Migrants; Table S1. Effectiveness and Cost-effectiveness
Search Strategy; Tables S2–S5. Study profile GRADE; Table S6. Chronic HCV burden in migrants: the 10
migrant groups from intermediate/high HCV prevalence countries with the highest number of HCV cases in host
EU/EEA countries.
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